Status:
COMPLETED
Contribution of Cerebral 18F-DOPA PET-CT Scan in High-grade Recurrent Gliomas
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
High Grade Glioma
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
High-grade gliomas represent 60 to 70% of adult glial tumors and are highly aggressive with average survival from 12 to 15 months for glioblastomas (WHO grade IV gliomas) and from 2 to more than 5 yea...
Detailed Description
The use of contrast enhancement in enhancing -T1 MRI, due to the rupture of the blood-brain barrier may underestimate the volume to be irradiated. The natural course of these gliomas after first irrad...
Eligibility Criteria
Inclusion
- Adult \> 18 and \< 75 years old
- Status WHO ≤ 2
- Histological diagnosis of WHO grade III or IV glioma, in local recurrence after radiochemotherapy (60Gy/30 sessions + concomitant TEMOZOLOMIDE), postoperatively or exclusively.
- Recurrence in the field of initial radiotherapy
- Indication for stereotactic radiotherapy alone, validated in neuro-oncology CPR.
- Patient affiliated to a social security system
- Patient able to give consent
Exclusion
- Contraindication to new radiotherapy
- First treatment other than standard radiochemotherapy (60Gy/30 session + concomitant TEMOZOLOMIDE), postoperative or exclusive.
- Contraindication to MRI and/or gadolinium injection
- Pregnancy, breastfeeding
- Follow-up of the patient impossible
- Persons deprived of liberty or under guardianship
Key Trial Info
Start Date :
May 18 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 3 2025
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT04766632
Start Date
May 18 2021
End Date
June 3 2025
Last Update
June 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU NANCY Brabois, nuclear medicine department
Vandœuvre-lès-Nancy, France, 54511